Home > Healthcare > Medical Devices > Diagnostic Devices > cystatin c assay market
Get a free sample of Cystatin C Assay Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Cystatin C Assay Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The cystatin C assay industry by product is categorized into kits, reagents, and analyzers. The kits segment garnered USD 116.8 million revenue size in the year 2023 and is projected to have the fastest-growing CAGR in the forecast period.
Therefore, the increasing preference for these kits will play a pivotal role in propelling the market growth.
Based on sample type, the market is segmented into blood and urine. Blood segment garnered USD 183.9 million revenue size in 2023.
Based on method, the market is segmented into enzyme-linked immunosorbent assay (ELISA), particle-enhanced turbidimetric immunoassay (PETIA), particle-enhanced nephelometric immunoassay (PENIA), chemiluminescent immunoassay (CLIA), immunofluorescence assay, and other methods. Enzyme-linked immunosorbent assay (ELISA) segment garnered USD 78.8 million revenue in 2023
Thus, its high sensitivity and specificity, quantitative capabilities, ease of use, adaptability to automation, cost-effectiveness, and widespread acceptance in both research and clinical settings is anticipated to boost demand for enzyme-linked immunosorbent assay (ELISA) method.
Based on application, the market is segmented into diagnostics and research. The diagnostics segment held substantial revenue in the market accounting for USD 192 million in the year 2023.
Based on end-use, the cystatin C assay market is segmented into hospitals, clinical laboratories, pharmaceutical and biotechnology companies, and other end-users. The hospital segment accounted for largest share of 32.3% in 2023 in the market. The large share of this segment can be attributed to large patient pool and easy access. Hospitals adhere to stringent quality control and assurance standards when conducting cystatin C assays. This ensures the accuracy and reliability of test results, meeting regulatory requirements.
The U.S. market accounted for USD 102.4 million revenue size in 2023 and is predicted to witness substantial market growth over the analysis timeline.
Market size for cystatin C assay was USD 269.6 million in 2023 and is expected to reach USD 522.6 billion by 2032 due to the increasing prevalence of chronic kidney diseases and in the surging need for early diagnosis, monitoring, and kidney stone management worldwide.
Cystatin C assay industry size from the kits products segment recorded USD 116.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 owing to their prominent role in providing laboratories and healthcare facilities with convenient and ready-to-use solutions.
U.S. industry size for cystatin C assay recorded USD 102.4 million in 2023 due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and the increasing prevalence of chronic kidney diseases in the region.
Siemens Healthineers AG, Abbott Laboratories, Beckman Coulter (Danaher Corporation), Thermo Fisher Scientific Inc, bioM